Skip to main content
TipRanks
Go Ultimate75% OFF

Bristol-Myers Squibb (BMY) Drug Pipeline

12,197 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
DeucravacitinibSystemic Lupus Erythematosus, Psoriasis, Psoriatic Arthritis, Sjögren's DiseasePhase IIINot Yet RecruitingContinued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersAug 25, 2026
Bms-986446Alzheimer's Disease, Healthy ParticipantsPhase IRecruitingA Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose AdministrationAug 19, 2026
Navlimetostat, [14C]Navlimetostat, Bms-986504Healthy Female ParticipantsPhase INot Yet RecruitingA Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female ParticipantsAug 18, 2026
Bms-986511Major Depressive DisorderPhase IINot Yet RecruitingA Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderAug 14, 2026
Golcadomide, Cc-99282, Bms-986369Kidney Failure, ChronicPhase IRecruitingA Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionAug 10, 2026
Carboplatin, Cisplatin, Pemetrexed, Osimertinib, Iza-Bren, Bms-986507Non-small Cell Lung CancerPhase IIIRecruitingStudy of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)Jun 26, 2026
Pumitamig, Pm8002, Imzokitug, Bnt327, Bms-986340Metastatic Non-Small Cell Lung Cancer (Nsclc), Locally Advanced Non-Small Cell Lung Cancer (Nsclc)Phase IIRecruitingA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Jun 26, 2026
Rosuvastatin, Dabigatran Etexilate, Famotidine, Bms-986533Healthy VolunteersPhase IRecruitingSingle and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy ParticipantsJun 01, 2026
Bms-986521Healthy VolunteersPhase IRecruitingA Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult ParticipantsMay 29, 2026
Zanzalintinib, Nivolumab, Cabozantinib, Enzalutamide, Atezolizumab, Prednisone, Abiraterone, Xl184, Xl092, CabometyxColorectal Cancer, Cancer, Prostate Cancer, Hepatocellular Carcinoma (Hcc), Pancreatic Neuroendocrine Tumors (Pnet), Extra-Pancreatic Net (Epnet), Differentiated Thyroid Cancer (Dtc), Renal Cell Carcinoma (Rcc), Non-Clear Cell Renal Cell Carcinoma (Nccrcc)Phase IIIEnrolling By InvitationLong-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyMay 27, 2026

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Bristol-Myers Squibb Company (BMY) have in its pipeline
Bristol-Myers Squibb BMY is currently developing the following drugs: Deucravacitinib, Bms-986446, Navlimetostat, [14C]Navlimetostat, Bms-986504, Bms-986511, Golcadomide, Cc-99282, Bms-986369, Carboplatin, Cisplatin, Pemetrexed, Osimertinib, Iza-Bren, Bms-986507, Pumitamig, Pm8002, Imzokitug, Bnt327, Bms-986340, Rosuvastatin, Dabigatran Etexilate, Famotidine, Bms-986533, Bms-986521, Zanzalintinib, Nivolumab, Cabozantinib, Enzalutamide, Atezolizumab, Prednisone, Abiraterone, Xl184, Xl092, Cabometyx, Navlimetostat, Bms-986504, Disp-10, Carboplatin, Gemcitabine, Paclitaxel, Nab-Paclitaxel, Pemetrexed, Pumitamig, Temozolomide, Bms-986504, Daraxonrasib, Nivolumab + Relatlimab Fdc, Bnt327, Mrtx1719, Navlimetostat, Nivolumab + Relatlimab, Bms-986213, Bms-986278, Admilparant, Moxifloxacin, Bms-986278, Bms-986528, Pembrolizumab, Pumitamig, Durvalumab, Pumitamig, Nivolumab, Bms-986525, Atezolizumab, Bevacizumab, Ipilimumab, Pumitamig, Nivolumab, Ipilimumab, Pumitamig, Cabozantinib, Karxt, Karxt, Karx-Ec, Temozolomide, Pumitamig, Bevacizumab, Bnt327, Pm8002, Bms-985521, Gemcitabine, Nab-Paclitaxel, Mfolfirinox, Pumitamig, Bms-986435, Myk-224, Admilparant, Rosuvastatin, Metformin, Bupropion, Omeprazole, Digoxin, Flurbiprofen, Repotrectinib, Gemcitabine, Cetuximab, Pembrolizumab, Nab-Paclitaxel, Bms-986523, Nivolumab, Folfox, Pumitamig, Capox, Bevacizumab, Folfiri, Folfox, Pumitamig, Capox, Xanomeline/Trospium Chloride, Karxt, Bms-986506, Bms-986454, Gemcitabine, Carboplatin, Eribulin, Pumitamig, Nab-Paclitaxel/Paclitaxel, Bms-986517. These drug candidates are in various stages of clinical development as the company works toward FDA approval.